Hoffmann Diane E, Javitt Gail H, Kelly Colleen R, Keller Josbert J, Baunwall Simon Mark Dahl, Hvas Christian Lodberg
University of Maryland Francis King Carey School of Law, Baltimore, MD, USA.
Hyman, Phelps & McNamara, Washington, DC, USA.
Gut Microbes. 2025 Dec;17(1):2493901. doi: 10.1080/19490976.2025.2493901. Epub 2025 Apr 29.
Fecal microbiota transplantation (FMT) is a procedure involving the transfer of intestinal microbiota from a healthy donor to a patient to restore a functional intestinal microbiome. First described in modern science in 1958, the use of FMT has been practiced for decades, but only during the past dozen years have clinical frameworks and legal regulations from competent authorities been developed. Future development of microbiota-derived medical therapies will be shaped by the regulatory frameworks of various jurisdictions. This review examines the historical development and status of FMT regulations in the United States and Europe, with particular attention to their respective approaches to ensuring the safety and quality of the therapeutic product and patient access.
粪便微生物群移植(FMT)是一种将健康供体的肠道微生物群转移到患者体内以恢复功能性肠道微生物组的程序。FMT于1958年在现代科学中首次被描述,其应用已经实践了数十年,但直到过去十几年才由主管当局制定了临床框架和法律法规。微生物衍生医学疗法的未来发展将受到各个司法管辖区监管框架的影响。本综述考察了美国和欧洲FMT法规的历史发展和现状,特别关注它们在确保治疗产品的安全性和质量以及患者可及性方面各自采取的方法。